7/102 sources · 2 publishersUpdated Oct 8, 23:27 UTC
Truist raises Amgen price target to $380, up from $362
Truist Securities lifted its price target for Amgen Inc. to $380 per share, up from $362, while keeping a Hold rating. The firm cited stronger pipeline prospects and higher revenue expectations for the third quarter of 2026. Truist also noted the stock was trading above its target at $409.77. The analyst forecast Q3 revenue of $10.23 billion and non‑GAAP EPS of $5.90.
Why it matters
Truist’s higher target suggests the analyst sees upside potential despite the current price exceeding the target, which may influence investor sentiment toward Amgen.
Key facts
- 1Truist raised its price target for Amgen to $380 from $362. tipranks.com
- 2Truist maintained a Hold rating on the stock. tipranks.com
- 3The stock was trading at $409.77 at the time of the note. investing.com
- 4Truist projects third‑quarter 2026 revenue of $10.23 billion. investing.com
- 5Truist projects third‑quarter 2026 non‑GAAP EPS of $5.90. investing.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.